ABSTRACT
Study aim - to elucidate possibilities of the use of precision administration of mononuclear bone marrow cells (MBMC) for the treatment of myocardial ischemia and heart failure. "Intramyocardial Multiple Precision Administration of Mononuclear Bone Marrow Cells in the Treatment of Myocardial Ischemia" was a double blind randomized placebo controlled study in which we included patients more or equal 6 months after Q-wave myocardial infarction with systolic myocardial dysfunction (ejection fraction <35%), not requiring myocardial revascularization, receiving stable optimal medical therapy for more or equal 8 weeks, and with implanted cardioverter-defibrillator. Transplantation of MBMC was guided by fluoroscopy and tridimensional NOGA XP Cardiac Navigation System. For assessment of efficacy of the method we used surrogate end points: decrease of number of fixed perfusion defects according to SPECT data and improvement of regional myocardial contractility according to data of echocardiography. Results of dynamic observation of the first experience of MBMC administration are presented in this paper.
Subject(s)
Bone Marrow Transplantation/methods , Heart Failure , Myocardial Infarction/complications , Myocardial Ischemia , Adult , Cardiovascular Agents/therapeutic use , Double-Blind Method , Female , Heart Failure/diagnosis , Heart Failure/etiology , Heart Failure/therapy , Heart Function Tests/methods , Humans , Male , Middle Aged , Monitoring, Physiologic/methods , Myocardial Contraction , Myocardial Ischemia/diagnosis , Myocardial Ischemia/etiology , Myocardial Ischemia/therapy , Radiography, Interventional/methods , Therapy, Computer-Assisted/methods , Tomography, Emission-Computed, Single-Photon , Treatment OutcomeABSTRACT
Two yeast recombinant vaccines were compared: the Russian hepatitis B Combiotech vaccine in a dose of 20 mg and the Recombivax-HB vaccine in a dose of 10 mg manufactured in the USA (Merk, Sharp and Dohme Ltd.). Both agents were found safe and low reactogenic. After a course of 3 vaccinations with the Russian vaccine 92.5 to 97.5% subjects vaccinated after the 0-1-2 months and 0-1-6 months protocols had high levels of specific antibodies. In the group vaccinated with the American vaccine, antibodies to HBsAg were found in the sera of 95 to 100% subjects. These results demonstrate high immunological activity of both Russian and American vaccines.
Subject(s)
Hepatitis B Vaccines/therapeutic use , Hepatitis B/prevention & control , Vaccines, Synthetic/therapeutic use , Adult , Hepatitis B/immunology , Hepatitis B Surface Antigens/analysis , HumansABSTRACT
The test-system has been elaborated for the determination of the ability of different antigens in the cultures of the mouse peritoneal macrophages. Measuring an intracellular acid phosphatase activity, reflecting the extent of the cell activation, was taken as a principle of this test-system. With the help of this test-system ability of a few antigens (lipopolysaccharide, polysaccharide, glycoprotein, protein and low molecular weight substances--peptide and glycopeptide) have been studied. It is testified that above mentioned antigens possessed different effects on the acid phosphatase activity.
Subject(s)
Acid Phosphatase/analysis , Antigens/immunology , Macrophages/immunology , Polysaccharides, Bacterial , Animals , Antigens, Bacterial/immunology , Cells, Cultured , Clinical Enzyme Tests , Culture Media , Macrophages/enzymology , Mice , Mice, Inbred CBA , PeritoneumABSTRACT
The treatment with concanavalin A (5 micrograms/ml) of mouse lymphocytes containing 70-72% of T cells entails an increase in the activity of acid phosphatase and a decrease in the activity of N-acetyl-beta-glucosaminidase. These changes were detectable 15 h after lymphocyte incubation with Con A. After 24 h of incubation acid phosphatase activity rose 2-fold whereas that of N-acetyl-beta-glucosaminidase dropped 45-50%. Possible mechanisms of these changes are discussed.
